<?xml version="1.0" encoding="utf-8"?>
<Document>
  <Do_id>21475126</Do_id>
  <Journal>Clinical advances in hematology &amp; oncology : H&amp;O</Journal>
  <Doc_title>New targets in advanced NSCLC: EML4-ALK.</Doc_title>
  <Doc_abstract>Targeted therapies aimed at inhibiting oncogenic tyrosine kinases are becoming commonplace in the treatment of cancer. The EML4-ALK fusion gene was first identified as a potentially targetable oncogenic driver in non-small cell lung cancer in 2007. A small molecule ALK inhibitor, crizotinib, may now be on the verge of approval by the US Food and Drug Administration for the treatment of ALK-rearranged lung cancer. Here we review the discovery of EML4-ALK, the development of clinical diagnostics for ALK rearrangements, the clinical epidemiology of lung cancers driven by EML4-ALK, and ongoing ALK inhibitor-based clinical trials.</Doc_abstract>
  <Doc_ChemicalList>EML4-ALK fusion protein, human;Oncogene Proteins, Fusion;Pyrazoles;Pyridines;crizotinib</Doc_ChemicalList>
  <Doc_meshdescriptors>Carcinoma, Non-Small-Cell Lung;Genetic Therapy;Humans;Lung Neoplasms;Oncogene Proteins, Fusion;Pyrazoles;Pyridines</Doc_meshdescriptors>
  <Doc_meshqualifiers>diagnosis;epidemiology;genetics;metabolism;therapy;diagnosis;epidemiology;genetics;metabolism;therapy;genetics;metabolism;therapeutic use;therapeutic use</Doc_meshqualifiers>
</Document>
